Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting

Kanellos Rafail Koustenis, Olga Anagnostou, Hariklia Kranidioti, Sofia Vasileiadi, Pinelopi Antonakaki, Evangelia Koutli, Paris Pantsas, Melanie Deutsch, Spilios Manolakopoulos

Medical School of National and Kapodistrian University of Athens, Hippokration General Hospital; Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece

Abstract

Background Direct-acting antivirals (DAAs) offer high cure rates in people who inject drugs (PWID) with hepatitis C virus (HCV) infection. There are concerns regarding lower response rates among PWID in real life. We evaluated the outcome of DAA therapy in PWID in a real-world setting and the factors that affect it.

Methods We performed a retrospective analysis of 174 PWID with chronic hepatitis C who started DAAs in a Greek liver clinic in collaboration with an addiction program. Patients who did not return for reassessment were considered as lost to follow up (LTFU). A logistic regression model was used to assess factors associated with a sustained virological response 12 weeks after treatment completion (SVR12) and LTFU.

Results Patients’ mean age was 48±9.2 years and 91/174 (52.3%) were attending opioid substitution treatment programs. Overall, 144/174 (82.8%) patients completed therapy and presented for SVR12 testing, 8/174 (4.6%) did not complete treatment and 22/174 (12.6%) were LTFU. Overall SVR12 was 79.9% (139/174). For those with an available SVR12 test the response rate reached 96.5% (139/144). Regression analysis did not indicate any significant association between patient characteristics and SVR12. Age <45 years and genotype 3 were independent predictors of LTFU. Parallel use was found to have a trend towards LTFU.

Conclusions HCV treatment by hepatologists and addiction specialists is feasible, effective and safe in a real-world setting. However, as 12% of patients appear to be LTFU, more emphasis should be placed on interventions guaranteeing follow up for SVR testing and general care.

Keywords Direct-acting antivirals, hepatitis C virus infection, people who inject drugs, sustained virological response, lost to follow up

Introduction

Approximately 10% of people with chronic hepatitis C virus (HCV) infection globally are past or current illicit drug users [1]. Sharing needles and syringes among people who inject drugs (PWID) is the main route of HCV transmission in developed countries. HCV infection poses an important health issue among PWID, while in many countries the burden of liver disease due to chronic hepatitis C in this population is expected to increase over the next decade [1,2]. Therefore, there is a need to prioritize PWID for scaling up HCV testing and treatment.

The clear benefit of antiviral therapy after the introduction of direct-acting antivirals (DAAs) [3,4], along with the ambitious goal of the World Health Organization (WHO) for HCV elimination [5] and the recent clinical guidelines [6,7], could not allay the concerns regarding adherence, reinfection and overall outcome of anti-HCV treatment in PWID. Several reports from different countries have shown that
treatment uptake still remains low [8] and many clinicians are reluctant to treat active PWID [9], while in many parts of the United States of America active substance use remains an important barrier to treatment uptake [10]. On the other hand, PWID are facing many other barriers, particularly to accessing medical care, with the majority of these patients never having been examined by an expert hepatologist, while DAAs can be prescribed only by expert physicians in large liver centers.

However, there is a large body of evidence that DAA therapy in PWID offers sustained virological response rates 12 weeks after treatment completion (SVR12) similar to those in non-PWID populations [11-16]. A reasonable concern in a marginalized population is compliance with treatment; indeed, although the proportion of patients lost to follow up (LTFU) is small in randomized clinical trials [13,17], data from real-world settings are scanty and conflicting [12,18-21]. The rate of LTFU and the factors that may affect engagement with treatment and follow up will add crucial information to improve HCV service delivery and treatment.

Greece has expressed its willingness to contribute to the WHO strategy for HCV elimination, by scaling-up treatment for HCV infection in both the general population and the vulnerable population of PWID. The prevalence of HCV infection in Greece is estimated to be between 0.83% and 1.79% [22], while 20-40% of persons with chronic hepatitis C have a history of illicit drug injections [23-25]. In the present study, our primary objective was to evaluate the clinical outcome of HCV treatment with DAAs in a Greek cohort of PWID, as assessed by SVR12, and secondarily to define factors that may influence this outcome. This national-based approach aims to add extra knowledge to the international guidelines that encourage physicians to treat HCV-infected PWID.

Patients and methods

Study design and participants - data collection

We conducted a retrospective analysis of a cohort that included PWID with chronic HCV infection who had been treated with DAAs in our tertiary liver center in Athens. More specifically, we analyzed data from all PWID who had detectable serum HCV RNA for at least 6 months and had started antiviral treatment with DAAs between 1 September 2014 and 1 June 2018. Individuals were classified as PWID if they had a history of any illicit drug injection at any time. Those who reported a history of illicit drug injection during the last 12 months or had a positive urinalysis were classified as PWID with parallel drug use. A history of previous anti-HCV therapy, decompensated liver disease, liver transplantation, hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfections, or parallel drug use were not considered exclusion criteria in our analysis. Opioid substitution treatment (OST) programs included substitution therapies with buprenorphine or methadone in a structured program under the supervision of a multidisciplinary health care team. Patients presented to our center either of their own volition or via collaboration with the practitioners at the addiction programs.

The decision for antiviral treatment initiation was made by an expert physician, and in case of patients attending OST programs by the interdisciplinary HCV group. We operate a specific outpatient clinic, once weekly, where PWID are examined by a group of addiction experts and hepatologists [26]. Apart from the stability of appointment attendance, mental or medical comorbidities and liver disease stages were also taken into consideration for treatment initiation. In Greece, reimbursement for DAAs was based on liver disease stages until September 2018, so until June 2017 only patients with fibrosis stage ≥F3 could receive DAA therapy. Between July 2017 and September 2018, public funding and DAA reimbursement was limited to patients with liver stiffness ≥F2, whereas patients with concomitant extrahepatic HCV manifestations and individuals with other comorbidities, such as hemoglobinopathies, end-stage renal disease, organ transplantation or HIV/HCV coinfection, were treated irrespectively of the liver stiffness score. The chosen elastography cutoff values for liver fibrosis stages were: stiffness <9 kPa, 9-12 kPa and >12kPa for no/mild/moderate fibrosis (Metavir Score F0-F1-F2), severe fibrosis (Metavir score F3), and cirrhosis (Metavir Score F4), respectively. The diagnosis of cirrhosis was based on the transient elastography score (>12 kPa), liver biopsy findings and clinical or imaging data.

We collected patients’ baseline and demographic characteristics as part of standard clinical care. During the first visit, a complete blood count, liver function tests, HBV/HCV, HIV serology, quantitative serum HCV RNA levels and HCV genotyping were determined using standard commercial assays. We also recorded all treatment medications, HCV treatment plans, all visits to our center, treatment completion data and SVR12 testing results.

The specific DAA treatment was determined according to the physician’s judgment, taking into account the HCV genotype, and the presence of cirrhosis and comorbidities. During the treatment period, all patients were assessed monthly in our department for treatment compliance, or earlier if possible adverse effects of therapy were present. SVR12 was defined as at least one polymerase chain reaction test with undetectable HCV RNA, 12 weeks after treatment completion. Individuals who did not complete the SVR12 testing within 24 weeks after treatment completion were considered as LTFU. Failure to respond to antiviral therapy was defined as detectable HCV RNA any time after treatment completion.

The study was approved by the Ethics committee of the Hippokration General Hospital of Athens and all the procedures followed were in accordance with the Helsinki Declaration.

Statistical analysis

Patient characteristics were compared using the Mann-Whitney test for continuous variables and the chi-square or Fisher’s exact test for categorical variables. Univariate and multivariable logistic regression analysis were applied for prediction of SVR12 or LTFU and 95% confidence intervals (95%CI) for the odds
ratios (OR) were calculated. Significant variables in the univariate analysis were included in the multivariate model. Statistical tests were performed using SPSS (version 25). A P-value <0.05 was considered statistically significant.

Results

Baseline characteristics

We enrolled 174 patients who started therapy with DAAs between 1 September 2014 and 1 June 2018 and were due for SVR12 testing by 31st December 2018. The baseline characteristics of our cohort are shown in Table 1. The patients had a mean age of 48±9.2 years and most were male (83.9%). Of the 174 PWID, 91 (52.3%) were attending OST programs during the DAA treatment period and 68 (39.1%) revealed parallel active drug use. Four patients (2.3%) had HBsAg detectable and were receiving tenofovir fumarate 245 mg daily, while 8 (4.6%) patients with HIV/HCV coinfection were under highly active antiretroviral therapy. Previous HCV treatment experience was reported by 44 of the 174 (25.3%) patients and 72 patients (41.4%) had evidence of cirrhosis. The most prevalent genotype was genotype 3 (61.5%), with genotype 1 following at a rate of 23%. There were no patients infected with genotype 5 or 6. Two patients had decompensated liver disease at baseline with Child-Pugh-Turcotte scores C and B, and model for end-stage liver disease scores 18 and 10, respectively. The DAA regimens and the number of patients per regimen are shown in Table 2.

Treatment outcomes

The vast majority of the patients (166/174, 95.4%) completed treatment. Eight of the 174 patients (4.6%) did not complete therapy: poor compliance was the main reason for early cessation (4/8 patients); one patient died early after treatment initiation; one patient discontinued treatment because of pregnancy; and 2 patients were diagnosed with malignancies (acute leukemia and rectal cancer) and discontinued DAA treatment on their own decision. Two of them, who had HCV testing approximately 1 year after treatment discontinuation, showed a sustained virologic response.

Between treatment initiation and the end of treatment (EoT), 4 (2.3%) of the 174 patients were LTFU, while 18 (10.3%) patients were LTFU after treatment completion; therefore, overall 22/174 (12.6%) patients were LTFU with no SVR12 test available.

Table 1 Baseline characteristics of PWID who initiated treatment with DAAs

| Characteristics | Value |
|-----------------|-------|
| Mean age±SD years | 48±9.2 |
| Male sex, n (%) | 146 (83.9%) |
| Addiction treatment program, n (%) | | |
| Methadone | 64 (36.8%) |
| Buprenorphine | 27 (15.5%) |
| Dry program | 14 (8%) |
| Parallel drug use, n (%) | 68 (39.1%) |
| Comorbidities, n (%) | 49 (28.2%) |
| HCV genotype, n (%) | | |
| 1a | 34 (19.5%) |
| 1b | 6 (3.5%) |
| 2 | 5 (2.9%) |
| 3 | 107 (61.5%) |
| 4 | 22 (12.6%) |
| Treatment-experienced, n (%) | 44 (25.3%) |
| HCV/HBV coinfection | 4 (2.3%) |
| HCV/HIV coinfection | 8 (4.6%) |
| Stiffness±SD kPa | 13.9±8.9 |
| Stage of fibrosis, n (%) | | |
| F0-F2 (none/mild/moderate fibrosis) | 70 (40.2%) |
| F3 (severe fibrosis) | 32 (18.4%) |
| F4 (cirrhosis) | 72 (41.4%) |
| • Decompensated cirrhosis | 2 (1.1%) |

PWID, people who inject drugs; DAAs, direct-acting antivirals; HBV, hepatitis B virus; HIV, human immunodeficiency virus; SD, standard deviation; HCV, hepatitis C virus

Table 2 Antiviral treatment options for the 174 PWID who initiated DAAs, n (%)  

| Treatment | No. of patients |
|-----------|----------------|
| SOF+RBV  | 4 (2.3) |
| SOF+DCV  | 2 (1.1) |
| SOF+DCV+RBV | 24 (13.8) |
| SOF/LDV  | 7 (4.0) |
| SOF/LDV+RBV | 4 (2.3) |
| 3D       | 3 (1.7) |
| 3D+RBV  | 24 (13.8) |
| 2D+RBV  | 10 (5.7) |
| SOF/VEL  | 50 (28.7) |
| SOF/VEL+RBV | 35 (20.1) |
| EBR/GZR  | 11 (6.3) |

PWID, people who inject drugs; DAAs, direct-acting antivirals; SOF, sofosbuvir; RBV, ribavirin; DCV, daclatasvir; LDV, ledipasvir; 2D, paritaprevir/ritonavir-ombitasvir; 3D, paritaprevir/ritonavir-ombitasvir/daclatasvir; VEL, velpatasvir; EBR, elbasvir; GZR, grazoprevir

or LTFU. Univariate logistic regression analysis demonstrated that age <45 years (OR 3.269, 95%CI 1.289-8.289; P=0.013), parallel drug use (OR 2.547, 95%CI 1.023-6.342; P=0.044) and genotype 3 (OR 4.659, 95%CI 1.322-16.420; P=0.017)
were significantly associated with LTFU. Multivariate analysis showed that age <45 years (OR 3.600, 95%CI 1.361-9.521; P=0.010) and genotype 3 (OR 5.443, 95%CI 1.492-19.861; P=0.010) were significantly associated with LTFU (Table 3). A significant trend towards LTFU was also observed for patients with parallel use (P=0.085).

In addition, univariate logistic regression analysis did not indicate a significant association between any of the baseline factors and the achievement of SVR12 in the ITT population (Table 4). Indicatively, SVR12 rates were similar between OST and non-OST groups (79.1% and 80.7%, respectively, P>0.05) as well as between cirrhotic and non-cirrhotic subgroups (80.6% and 79.4%, respectively, P>0.05).

**Safety and tolerability**

No serious adverse event was reported during the treatment period and no patient stopped therapy because of adverse events. Anemia (hemoglobin <10 g/dL) was reported in 2 patients receiving ribavirin and resolved after dose reduction in both cases. One patient died from progressive liver disease during the first month of treatment. No deaths or hospital admissions due to opioid overdose or other drug-related problems were reported.

**Discussion**

In this study we reported real-world experience of more than 3 and a half years from a cohort of PWID with chronic HCV infection treated with DAAs. Our results clearly showed that DAAs are very effective and well tolerated in this population, achieving an SVR in 96.5% of the patients who had an HCV RNA test available by the 12th week post therapy. However, in the ITT analysis a drop in SVR12 rate (79.9%) was recorded. This was attributed mainly to the LTFU patients, highlighting that guaranteeing the follow up and SVR12 visit represents a challenging goal.

The efficacy of DAA therapy in PWID with HCV infection has been examined in 2 large prospective studies, in a number of post hoc analyses and in several real world studies [11-13,16,17,19,20,27-29]. In the prospective cohorts, ITT SVR12 rates were 94% and 92%, with 3% of the patients being LTFU [13,17]. The well-organized prospective selection of the patients, in combination with the meticulous follow-up methodology, might be the explanation for the high adherence and SVR12 rates. The 96.5% SVR12 rate in our patients who had an HCV RNA test 12 weeks post treatment is comparable with the results of these prospective studies, demonstrating that DAAs can offer high SVR rates in PWID, similar to those reported in the general population. However, one might argue that the practices and methodology of prospective clinical trials cannot be reproduced in the real world, particularly in PWID.
In contrast, the association between genotype 3 and LTFU is difficult to explain. It is known that HCV is transmitted through injecting networks, which have significant differences in epidemiological and disease-related characteristics. Our analysis is not sufficient to confirm or rule out the likelihood that genotype 3 predominates in networks composed of individuals with a chaotic lifestyle and a higher probability of failure to comply with treatment and follow-up schedules [32].

Interestingly, in the multivariate regression model we observed a significant tendency towards LTFU in those PWID with parallel active drug use at the time of DAA therapy. The results are in accordance with our previous analysis regarding treatment uptake: a proportion of PWID with HCV infection did not start treatment, despite the availability DAA, and the probability of treatment initiation was negatively associated with ongoing benzodiazepine use [33]. Therefore, further investigation in order to explore the associations between type of use, mental comorbidities and LTFU will reveal the importance of our finding.

Treatment adherence-enhancing strategies, including special nurses engaged in hepatitis C treatment in the hospital settings, could be a promising approach to deal with the problem of LTFU in this marginalized population. However, the implementation of such an approach is problematic, as it is associated with a cost increase that is not feasible for the majority of countries; our data are therefore of clinical importance, because intensifying support and follow-up visits only for those PWID who are at higher risk of being lost could reduce the LTFU rates.

Overall, DAA therapy was well-tolerated and safe; 3 patients discontinued treatment for non-liver-related reasons and 1 with decompensated disease at baseline died from liver failure. In addition, the most common adverse event was anemia, which was observed in 2 cirrhotic patients receiving ribavirin. Neither of these patients needed to discontinue treatment and their anemia improved with ribavirin dose reduction. In addition, none of the treated PWID developed hepatocellular carcinoma between treatment initiation and SVR12 testing.

Our study had several limitations, mostly related with the design. It was a single-center retrospective analysis and therefore the results should not be generalized without caution. Incomplete or missing data, entry errors and differences between active or former drug users are possible in a study with such a design. However, despite the above limitations our data points were complete (>95%) as regards the vast majority of the parameters analyzed. Furthermore, we included patients who represented all subgroups of PWID in real-world settings, therefore the results should not be generalized without caution. Incomplete or missing data, entry errors and differences between active or former drug users are possible in a study with such a design. However, despite the above limitations our data points were complete (>95%) as regards the vast majority of the parameters analyzed. Furthermore, we included patients who represented all subgroups of PWID in real-world settings, therefore the results should not be generalized without caution. Incomplete or missing data, entry errors and differences between active or former drug users are possible in a study with such a design. However, despite the above limitations our data points were complete (>95%) as regards the vast majority of the parameters analyzed. Furthermore, we included patients who represented all subgroups of PWID in real-world settings, therefore the results should not be generalized without caution.

In conclusion, our results confirm the excellent efficacy of DAAs in PWID with HCV infection; therefore, PWID should no longer face barriers to HCV treatment access. However, in a real-world setting 1 of 10 PWID is LTFU after DAA therapy completion. As a lack of follow up in this vulnerable population could have unfavorable consequences, we need more real-world data in order to develop strategies to reduce LTFU, improve care and testing and get closer to HCV elimination.

### Table 4 Logistic regression analysis for predictors of SVR12 (ITT population)

| Variable                | Univariate analysis | P-value |
|-------------------------|---------------------|---------|
| Age <45 years           | 1.225 (0.359-4.183) | 0.746   |
| Male sex                | 2.632 (0.327-21.179)| 0.363   |
| Genotype 3              | 1.658 (0.529-5.193) | 0.386   |
| Cirrhosis               | 0.448 (0.139-1.438) | 0.177   |
| OST                     | 0.921 (0.295-2.880) | 0.888   |
| Parallel drug use       | 0.319 (0.099-1.030) | 0.056   |
| Comorbidities           | 0.423 (0.134-1.341) | 0.144   |
| HIV                     | 0.448 (0.048-4.151) | 0.479   |
| Past treatment          | 0.757 (0.219-2.613) | 0.660   |

SVR12, Sustained virological response 12 weeks after the end of treatment; OST, opioid substitution treatment; ITT, intention-to-treat; HIV, human immunodeficiency virus; OR, odds ratio; CI, confidence interval.
Summary Box

What is already known:

- Direct-acting-antivirals (DAAs) are highly effective for the treatment of hepatitis C virus (HCV) infection
- Compared to the general population, DAAs have shown similar efficacy in clinical trials in people who inject drugs (PWID) and have HCV infection
- There has been evidence for lower response rates for PWID in a real-life setting
- Adherence to DAA therapy and loss to follow up (LTFU) during treatment are major concerns regarding antiviral treatment in the PWID population

What the new findings are:

- Our real-world data confirm the high rates of sustained virological response (SVR) following DAA therapy in PWID
- Approximately 1 of 10 PWID was LTFU during or after treatment completion, with no SVR test available
- LTFU seems to be related with younger age and genotype 3
- Parallel drug use was associated with a trend towards LTFU

References

1. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
2. Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol 2014;28:243-250.
3. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-1609.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
5. The Lancet. Towards elimination of viral hepatitis by 2030. Lancet 2016;388:306.
6. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461-511.
7. Grebely J, Haire B, Taylor LE, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? J Hepatol 2015;63:779-782.
8. Jain MK, Thamer M, Therapondos G, et al. Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period? Hepatology 2019;69:51-63.
9. Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vilahov D, Page KA. Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse 2016;51:1218-1223.
10. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-223.
11. Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting. Open Forum Infect Dis 2018;5:eofy120.
12. Christensen S, Buggisch P, Mauss S, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction 2018;113:886-882.
13. Dore GJ, Altice F, Litwin AH, et al; C-EDGE CO-STAR Study Group. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-634.
14. Grebely J, Mauss S, Brown A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of Phase 3 ION trials. Clin Infect Dis 2016;63:1405-1411.
15. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of Phase 3 ASTRAL trials. Clin Infect Dis 2016;63:1479-1481.
16. Bielen R, Moreno C, Van Vlierberghe H, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend 2017;177:214-220.
17. Grebely J, Dalgaard O, Conway B, et al; SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol 2018;3:153-161.
18. Boglione I, Mornese Pinna S, De Nicolò A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. J Viral Hepat 2017;24:850-857.
19. Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abuse Treat 2017;58:49-53.
20. Mason K, Dodd Z, Guyton M, et al. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 2017;47:202-208.
21. Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196-201.
22. Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephony survey. J Viral Hepat 2015;22:409–415.
23. Giannousis IP, Papatheodoridis GV, Deutsch MJ, et al. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol 2010;22:172–179.
24. Sypsa V, Touloumi G, Tassopoulos NC, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004;11:366-374.
25. Triantos C, Konstantakis C, Tselekouni P, Kalafateli M, Aggeletopoulou I, Manolakopoulos S. Epidemiology of hepatitis C
in Greece. *World J Gastroenterol* 2016;22:8094-8102.

26. Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. *Liver Int* 2010;30:1454-1460.

27. Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network. *Int J Drug Policy* 2017;47:216-220.

28. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. *Int J Drug Policy* 2017;47:209-215.

29. Winkel TM, Hinrichsen H, Sarrazin C, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. *J Viral Hepat* 2017;24:840-849.

30. Koustenis K-R, Koutli E, Kranidioti H, et al. Tu1506 – Adherence to follow-up of people who inject drugs (PWID) after the successful treatment of chronic hepatitis C with direct-acting antivirals (DAA). *Gastroenterology* 2019;156:S-1346.

31. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2018;3:754-767.

32. Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. *Hepatolology* 2014;60:1861-1870.

33. Anagnostou O, Kranidioti C, Micha K, et al. Is the availability of direct antiviral agents (DAAs) enough to treat chronic hepatitis C (CHC) and achieve HCV elimination among people who use drugs (PWUD)? What do the real world data suggest? 7th International Symposium on Hepatitis Care in Substance Users. Cascais/Portugal, 19-21 September 2018.